Header Ads

  • INA BREAKING NEWS

    New Delhi: New partnership to augment advancements in biopharmaceuticals.

    New Delhi: (India Science Wire) The Centre for Cellular and Molecular Platform (C-CAMP) and Agilent Technologies recently signed an agreement to jointly take up research and technology development in the biosimilars and biopharmaceuticals sector. The collaborative endeavor will primarily focus on mass spectrometry-based biotherapeutics/biosimilar characterization; a platform C-CAMP upholds with its existing state-of-the-art mass spectrometry facilities across proteomics, metabolomics, lipidomics, glycomics, and biologics research. 

    As part of the agreed-upon arrangements, both organizations will leverage each other’s capabilities to hold joint training sessions and seminars for researchers across biopharma/ biosimilars start-ups and established companies. C-CAMP and Agilent will collaborate on product development and services for the biopharmaceutical industry, using the high-end scientific infrastructures and skill sets that both Agilent and C-CAMP share. 

    “C-CAMP is steadily growing in the area of biopharmaceuticals and this partnership will greatly benefit the delivery of deep-science technologies to the biopharma sector. With this MoU, the start-ups associated with C-CAMP can easily access their high-end mass spectrometry solutions and technologies,” said Dr. Taslimarif Saiyed, C-CAMP CEO & Director 

    Dr. Shirshendu Mukherjee, Mission Director, Biotech Industry Research Assistance Council (BIRAC), congratulated both organizations for this partnership.

    “Science should not be limited to only bench level research and at BIRAC we are proud to have worked closely with C-CAMP in scouting for cutting-edge scientific ideas, converting them to technologies and solving important challenges while also exploiting their commercial potential. This partnership is a win-win for both C-CAMP and Agilent as it will provide access to high-end technology platforms such as Agilent’s to researchers, innovators and startups during the crucial product development phase," Dr. Mukherjee said.

    Highlighting the value of the collaboration, Dr. Samir Vyas, Country General Manager, Agilent India, said, “This is a unique collaboration in India where Agilent’s partnership has a greater vision to align with a flagship program named ‘Innovate in India (I3)’, enabling an ecosystem to promote entrepreneurship and manufacturing capabilities. This (I3) is an industry-academia mission to accelerate biopharmaceutical development in India and has been approved by the Government of India. With this, many of the upcoming and established biopharma start-ups would get opportunity to access the end-to-end biopharma workflow solutions from Agilent while leveraging on C-CAMP’s industry interface.” 

    C-CAMP facilitates bioscience research and innovation by providing training and services, in addition to funding, incubation, and entrepreneurship development support. The organization is registered under the United States Food and Drug Administration (US FDA) to perform analyses of active pharmaceutical ingredients, drug products, and drug substances.  It has directly supported 300+ start-ups over half a decade across the country in healthcare, agriculture, and the environment. C-CAMP has established 15 state-of-the-art technology platforms for facilitating cutting-edge research in biosciences. 

    Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward advancing the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to customers' most challenging questions.

    With Agilent’s support, C-CAMP will be catalysing more research and development of biopharmaceuticals in compliance with the global regulatory framework in India.

     (India Science Wire)


    Post Top Ad


    Post Bottom Ad


    Blogger द्वारा संचालित.